LDLR and ovarian carcinoma: It would be interesting to see the further development of nanoparticle targeting of LDLR and SR-B1 in preclinical studies involving for example several patient-derived breast and ovarian cancer tumor organoids with varying receptor expression levels and patterns, to support their potential usability in clinic.